RU2013158256A - АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα - Google Patents
АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα Download PDFInfo
- Publication number
- RU2013158256A RU2013158256A RU2013158256/15A RU2013158256A RU2013158256A RU 2013158256 A RU2013158256 A RU 2013158256A RU 2013158256/15 A RU2013158256/15 A RU 2013158256/15A RU 2013158256 A RU2013158256 A RU 2013158256A RU 2013158256 A RU2013158256 A RU 2013158256A
- Authority
- RU
- Russia
- Prior art keywords
- tnfα
- labeled
- autoantibodies
- level
- drug
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rehabilitation Therapy (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505031P | 2011-07-06 | 2011-07-06 | |
| US61/505,031 | 2011-07-06 | ||
| US201161528072P | 2011-08-26 | 2011-08-26 | |
| US61/528,072 | 2011-08-26 | ||
| US201161535884P | 2011-09-16 | 2011-09-16 | |
| US61/535,884 | 2011-09-16 | ||
| PCT/US2012/045794 WO2013006810A1 (en) | 2011-07-06 | 2012-07-06 | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013158256A true RU2013158256A (ru) | 2015-07-10 |
Family
ID=46551894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013158256/15A RU2013158256A (ru) | 2011-07-06 | 2012-07-06 | АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9465027B2 (enExample) |
| EP (2) | EP2729807B1 (enExample) |
| JP (1) | JP6181646B2 (enExample) |
| KR (1) | KR20140047628A (enExample) |
| CN (1) | CN103782172A (enExample) |
| AU (2) | AU2012278802B2 (enExample) |
| CA (1) | CA2840232A1 (enExample) |
| MX (1) | MX343324B (enExample) |
| RU (1) | RU2013158256A (enExample) |
| SG (1) | SG10201605516YA (enExample) |
| WO (1) | WO2013006810A1 (enExample) |
| ZA (1) | ZA201309703B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009076323A2 (en) | 2007-12-06 | 2009-06-18 | Genalyte Inc. | Monitoring enzymatic process |
| EP2347247B1 (en) | 2008-10-27 | 2019-06-26 | Genalyte, Inc. | Biosensors based on optical probing and sensing |
| CN104634955B (zh) | 2009-10-26 | 2016-09-14 | 雀巢产品技术援助有限公司 | 检测抗-tnf药物和自身抗体的试验 |
| WO2012054532A1 (en) | 2010-10-18 | 2012-04-26 | Prometheus Laboratories Inc. | Methods for determining anti-drug antibody isotypes |
| WO2013006810A1 (en) | 2011-07-06 | 2013-01-10 | Nestec Sa | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
| ES2638971T3 (es) | 2012-10-05 | 2017-10-24 | Nestec S.A. | Métodos para predecir y monitorizar la cicatrización de la mucosa |
| BR112015012482A2 (pt) * | 2012-11-30 | 2017-07-11 | Nestec Sa | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos |
| WO2014122600A1 (en) | 2013-02-05 | 2014-08-14 | Nestec S.A. | Methods of selecting combination therapy for colorectal cancer patients |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| EP3654037A1 (en) | 2013-12-03 | 2020-05-20 | Prometheus Biosciences, Inc. | Methods for predicting post-operative recurrence of crohn's disease |
| WO2015110989A1 (en) | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
| RU2017122720A (ru) | 2014-12-05 | 2019-01-10 | Нестек С.А. | Непрямые однородные анализы по изменению подвижности для детекции биологических препаратов в образцах пациента |
| CN105277682A (zh) * | 2015-11-17 | 2016-01-27 | 苏州浩欧博生物医药有限公司 | 一种抗TNF-α单抗药物抗体检测试剂盒 |
| US11119096B2 (en) * | 2016-07-08 | 2021-09-14 | W. Health L.P. | Universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples |
| EP3990922A1 (en) * | 2019-06-25 | 2022-05-04 | ProciseDx Inc. | Detection of anti-tnf alpha drug biologics and anti-drug antibodies |
| KR102626197B1 (ko) * | 2020-11-19 | 2024-01-18 | 바디텍메드(주) | 항 약물 항체의 수준을 정확하게 정량화하는 방법 |
| CN112730846B (zh) * | 2020-12-18 | 2023-12-15 | 安渡生物医药(杭州)有限公司 | 一种用于小鼠血样检测免疫复合物的方法 |
| CN114236139A (zh) * | 2021-12-30 | 2022-03-25 | 苏州和锐生物科技有限公司 | 一种TNF-α生物制剂的抗体检测试剂盒、制备方法 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US286774A (en) | 1883-10-16 | Door-hanger | ||
| US5700466A (en) | 1981-09-08 | 1997-12-23 | The Rockefeller University | Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor |
| US4459359A (en) | 1981-11-19 | 1984-07-10 | New York Blood Center, Inc. | Sensitive immunoassays of antigens or antibodies sequestered within immune complexes |
| US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US4857456A (en) | 1985-04-30 | 1989-08-15 | The Regents Of The University Of California | Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders |
| FR2590674B1 (fr) | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| US5223395A (en) | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
| EP0440044A1 (en) | 1990-01-31 | 1991-08-07 | Abbott Laboratories | Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing |
| US5094740A (en) | 1990-02-16 | 1992-03-10 | Glycomed, Inc. | Two-dimensional electrophoretic separation of carbohydrates |
| GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5582998A (en) | 1991-06-19 | 1996-12-10 | Boehringer Ingelheim International Gmbh | Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor |
| JPH0566222A (ja) | 1991-09-09 | 1993-03-19 | Tosoh Corp | 物質の分析方法 |
| PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| JPH07110331A (ja) | 1993-09-07 | 1995-04-25 | Wako Pure Chem Ind Ltd | ヒト補体価測定方法及びヒト補体価測定用試薬組成物 |
| DE69426223T2 (de) | 1993-09-07 | 2001-05-23 | Wako Pure Chemical Industries, Ltd. | Verfahren und Reagenz zur Messung der Komplementaktivität |
| JPH07140144A (ja) * | 1993-11-19 | 1995-06-02 | S R L:Kk | アレルゲン特異的ＩｇＥ抗体の測定方法および抗原抗体複合体の測定方法 |
| EP0796280B1 (en) | 1994-12-28 | 2003-03-26 | University Of Kentucky | Murine monoclonal anti-idiotype antibody 3h1 |
| US6903183B1 (en) | 1996-06-07 | 2005-06-07 | Texas Tech University Health Services Center | Compositions and methods for regulation of steroidogenesis |
| JP3718435B2 (ja) | 1996-08-12 | 2005-11-24 | 積水化学工業株式会社 | 細胞機能測定用容器及び細胞機能測定方法 |
| EP0882984B1 (en) | 1996-08-12 | 2010-10-06 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Containers and kits for the determination of cell functions, and method for the determination thereof |
| US6391622B1 (en) | 1997-04-04 | 2002-05-21 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
| US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
| DE19858777B4 (de) | 1998-12-18 | 2006-07-27 | Delta Biotechnology Ltd. | Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen |
| US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
| WO2001044472A1 (en) | 1999-12-16 | 2001-06-21 | Amgen, Inc. | Tnfr/opg-like molecules and uses thereof |
| US7323552B2 (en) | 2000-07-31 | 2008-01-29 | The General Hospital Corporation | Variant integrin polypeptides and uses thereof |
| JP4287147B2 (ja) * | 2000-11-02 | 2009-07-01 | イミュノセルラー・セラピューティクス・リミテッド | 小細胞肺癌（ｓｃｌｃ）の検出および治療のためのモノクローナル抗体および細胞表面抗原 |
| EP1379554A2 (en) | 2001-02-21 | 2004-01-14 | Curagen Corporation | Proteins, polynucleotides encoding them and methods of using the same |
| EP1637601A3 (en) | 2001-02-21 | 2006-03-29 | Curagen Corporation | Proteins, polynucleotides encoding them and methods of using the same |
| ATE476654T1 (de) | 2001-03-02 | 2010-08-15 | Activx Biosciences Inc | Plattform für protein-profiling |
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030040027A1 (en) | 2001-08-16 | 2003-02-27 | Gerd Ritter | Method for determining protein component in a biological sample |
| AU2002351957B2 (en) | 2001-11-12 | 2009-09-03 | Merck Patent Gmbh | Modified anti-TNF alpha antibody |
| AU2002347152A1 (en) | 2001-12-05 | 2003-06-17 | Cangene Corporation | Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection |
| GB0208817D0 (en) | 2002-04-17 | 2002-05-29 | European Molecular Biology Lab Embl | Method for producing monoclonal antibodies |
| US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| JP2006509724A (ja) | 2002-08-01 | 2006-03-23 | ワイス | 炎症及びアポトーシスに関係する方法及び試薬 |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| US7662569B2 (en) | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
| EP1718327B1 (en) * | 2003-06-20 | 2015-01-07 | University of Florida | Biomarkers for differentiating between type 1 and type 2 diabetes |
| SG145712A1 (en) | 2003-08-01 | 2008-09-29 | Amgen Inc | Crystalline tumor necrosis factor receptor 2 polypeptides |
| JP2007528868A (ja) | 2003-08-14 | 2007-10-18 | ワイス | 抗ルイスｙ抗イディオタイプ抗体およびその使用 |
| EP1519194A1 (en) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
| US7939634B2 (en) | 2004-01-27 | 2011-05-10 | Compugen Ltd. | Polynucleotides encoding polypeptides and methods using same |
| US20090275496A1 (en) | 2004-05-07 | 2009-11-05 | Peptimmune, Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
| EP1769244A4 (en) | 2004-06-30 | 2008-05-14 | Dow Kenneth Centocor Inc | DETECTION OR MEASUREMENT OF ANTIGEN PROTEIN ANTIBODIES IN BIOLOGICAL TISSUE OR SAMPLES |
| US20060253263A1 (en) | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
| US7601335B2 (en) | 2005-05-20 | 2009-10-13 | Genentech, Inc. | Pretreatment of a biological sample from an autoimmune disease subject |
| SG164379A1 (en) | 2005-07-21 | 2010-09-29 | Genmab As | Potency assays for antibody drug substance binding to an fc receptor |
| EP1937307A4 (en) | 2005-09-14 | 2009-05-13 | Hutchinson Fred Cancer Res | SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS |
| US7542502B2 (en) | 2005-09-27 | 2009-06-02 | Cymer, Inc. | Thermal-expansion tolerant, preionizer electrode for a gas discharge laser |
| US7611702B2 (en) | 2005-11-08 | 2009-11-03 | Medarex, Inc. | TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
| JP2007147367A (ja) | 2005-11-25 | 2007-06-14 | Sekisui Chem Co Ltd | サイトカイン産生能の測定方法 |
| DE102005057920A1 (de) | 2005-12-02 | 2007-06-28 | Strohner, Pavel, Dr. | Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben |
| EP1857559A1 (en) * | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
| US20100130367A1 (en) | 2006-07-11 | 2010-05-27 | Drexel University | Methods of Quantitatively Assessing Inflammation with Biosensing Nanoparticles |
| US20080286774A1 (en) | 2007-05-16 | 2008-11-20 | The Regents Of The University Of California | Real-time individualized therapy evaluation |
| NZ582618A (en) | 2007-07-13 | 2012-07-27 | Prometheus Lab Inc | Drug selection for lung cancer therapy using antibody-based arrays |
| US20090035216A1 (en) * | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
| EP2200613B1 (en) | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
| CN101214372A (zh) * | 2008-01-04 | 2008-07-09 | 中国人民解放军第四军医大学 | 一种体内诱导出针对TNF-α分子的自身抗体的蛋白疫苗的构建方法 |
| WO2009091240A1 (en) | 2008-01-15 | 2009-07-23 | Stichting Sanquin Bloedvoorziening | Method and kits for detecting antibodies against therapeutic antibodies |
| CN102016552A (zh) | 2008-03-05 | 2011-04-13 | 神谷来克斯公司 | 用于分子的高灵敏性检测的方法和组合物 |
| CN104634955B (zh) | 2009-10-26 | 2016-09-14 | 雀巢产品技术援助有限公司 | 检测抗-tnf药物和自身抗体的试验 |
| JP5066222B2 (ja) | 2010-05-31 | 2012-11-07 | 三菱電機株式会社 | ネットワーク解析支援装置、ネットワーク解析支援方法及びプログラム |
| CN103261222B (zh) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | 抗体衍生物 |
| WO2012054532A1 (en) | 2010-10-18 | 2012-04-26 | Prometheus Laboratories Inc. | Methods for determining anti-drug antibody isotypes |
| MX343327B (es) | 2011-02-17 | 2016-11-01 | Nestec Sa | Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. |
| UY34054A (es) | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| AU2012277185A1 (en) | 2011-06-30 | 2014-02-13 | Gene Techno Science Co., Ltd. | Soluble integrin alpha4 mutant |
| WO2013006810A1 (en) | 2011-07-06 | 2013-01-10 | Nestec Sa | Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha |
| US20130266963A1 (en) | 2011-07-06 | 2013-10-10 | Nestec S.A. | Assay for detecting neutralizing autoantibodies to biologic therapy |
| US20130295685A1 (en) | 2012-04-10 | 2013-11-07 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies |
| US20140051184A1 (en) | 2012-08-15 | 2014-02-20 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto |
| BR112015012482A2 (pt) | 2012-11-30 | 2017-07-11 | Nestec Sa | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos |
| CN105814081B (zh) | 2013-11-13 | 2021-02-02 | 辉瑞大药厂 | 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途 |
| RU2017122720A (ru) | 2014-12-05 | 2019-01-10 | Нестек С.А. | Непрямые однородные анализы по изменению подвижности для детекции биологических препаратов в образцах пациента |
| KR102423893B1 (ko) | 2015-03-31 | 2022-07-21 | 삼성디스플레이 주식회사 | 플렉서블 표시 장치 |
| AU2017378393B2 (en) | 2016-12-14 | 2023-03-09 | Bt Bidco, Inc. | Treatment of a disease of the gastrointestinal tract with a TNF inhibitor |
-
2012
- 2012-07-06 WO PCT/US2012/045794 patent/WO2013006810A1/en not_active Ceased
- 2012-07-06 CN CN201280043142.5A patent/CN103782172A/zh active Pending
- 2012-07-06 EP EP12738310.7A patent/EP2729807B1/en active Active
- 2012-07-06 AU AU2012278802A patent/AU2012278802B2/en not_active Ceased
- 2012-07-06 CA CA2840232A patent/CA2840232A1/en not_active Abandoned
- 2012-07-06 KR KR1020137034951A patent/KR20140047628A/ko not_active Withdrawn
- 2012-07-06 MX MX2013015420A patent/MX343324B/es active IP Right Grant
- 2012-07-06 EP EP16177029.2A patent/EP3130921B1/en not_active Not-in-force
- 2012-07-06 SG SG10201605516YA patent/SG10201605516YA/en unknown
- 2012-07-06 RU RU2013158256/15A patent/RU2013158256A/ru not_active Application Discontinuation
- 2012-07-06 JP JP2014519077A patent/JP6181646B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-20 ZA ZA2013/09703A patent/ZA201309703B/en unknown
- 2013-12-30 US US14/144,261 patent/US9465027B2/en active Active
-
2016
- 2016-02-25 AU AU2016201196A patent/AU2016201196B2/en not_active Ceased
- 2016-09-01 US US15/254,934 patent/US10794906B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1194467A1 (zh) | 2014-10-17 |
| EP2729807A1 (en) | 2014-05-14 |
| AU2012278802B2 (en) | 2015-11-26 |
| SG10201605516YA (en) | 2016-08-30 |
| MX2013015420A (es) | 2015-01-22 |
| EP3130921B1 (en) | 2018-09-12 |
| CN103782172A (zh) | 2014-05-07 |
| KR20140047628A (ko) | 2014-04-22 |
| AU2012278802A1 (en) | 2013-05-02 |
| WO2013006810A1 (en) | 2013-01-10 |
| ZA201309703B (en) | 2019-09-25 |
| MX343324B (es) | 2016-11-01 |
| US20140186973A1 (en) | 2014-07-03 |
| US20170176433A1 (en) | 2017-06-22 |
| CA2840232A1 (en) | 2013-01-10 |
| US9465027B2 (en) | 2016-10-11 |
| NZ619172A (en) | 2016-01-29 |
| EP3130921A1 (en) | 2017-02-15 |
| AU2016201196B2 (en) | 2018-01-25 |
| EP2729807B1 (en) | 2016-08-17 |
| JP2014525036A (ja) | 2014-09-25 |
| US10794906B2 (en) | 2020-10-06 |
| AU2016201196A1 (en) | 2016-03-17 |
| JP6181646B2 (ja) | 2017-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015125739A (ru) | Тесты детекции нейтрализующих аутоантител для биологической терапии | |
| Teunissen et al. | Body fluid biomarkers for multiple sclerosis—the long road to clinical application | |
| Ruiz-Argüello et al. | Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars | |
| JP2014525036A5 (enExample) | ||
| Steenholdt et al. | Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post HocAnalysis of a Randomized Controlled Trial | |
| Willrich et al. | Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC–MS/MS | |
| US9651560B2 (en) | Methods for detecting antibodies | |
| RU2013142278A (ru) | ТЕСТЫ ДЛЯ ДЕТЕКЦИИ АУТОАНТИТЕЛ К АНТИ-TNFα ЛЕКАРСТВЕННЫМ СРЕДСТВАМ | |
| Cludts et al. | Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab | |
| RU2012120722A (ru) | Способы выявления онкогенных слитых белков, основанные на анализе близкого взаимного расположения | |
| JP2015517801A5 (enExample) | ||
| Pavlov et al. | Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab | |
| Ogrič et al. | Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits | |
| Seaman et al. | Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis | |
| CN106706912A (zh) | 诊断炎症相关肝癌的标志物及其应用 | |
| EP3008469A2 (en) | Methods for predicting rheumatoid arthritis treatment response | |
| Di Santo et al. | Quantitative evaluation of adalimumab and anti-adalimumab antibodies in sera using a surface plasmon resonance biosensor | |
| RU2011150291A (ru) | Фосфодиэстераза-9а в качестве маркера злокачественной опухоли предстательной железы | |
| JPWO2020218121A5 (enExample) | ||
| Real-Fernández et al. | Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques | |
| Thoren et al. | Quantitation of infliximab and detection of antidrug antibodies in serum by use of surface plasmon resonance | |
| RU2745060C2 (ru) | Биомаркеры для комбинированной терапии, включающей ленватиниб и эверолимус | |
| JP6800208B2 (ja) | 肝細胞増殖因子（ｈｇｆ）のｐｄマーカー | |
| Palarasah et al. | The contact system in chronic kidney disease and hemodialysis–A cross-sectional study | |
| Willrich et al. | Comparison of clinical laboratory assays for measuring serum infliximab and antibodies to infliximab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20170713 |